Ann: MSB Q1 Financial Results and Operational Highlights, page-40

I wish they call it 'degenerative disc disease' which is what they are really treating. Chronic lower back pain is so bloody vague. The efficacy and novetly in MSB's treatments are their ability to repair damaged tissue. Sure the relief of pain is in part the anti-inflammatory effects, but often a bi-product of the repair mechanisms working and improvement of the tissue functionality.

MSB understandably holds off on the mechanism of actions because its difficult to prove (and you get chastised if you have anything but precise scientific RCT data on each action to the nth degree which is impossible) but it likely also reverse the pathophysiological processes evident and repairing damaged tissue to some degree.

A good insight to MSc's in DDD here for a newbie:


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347696/

Sorry back to the matter in hand. Great job on debt restructure, cash burn slow at present with most trials done and now onwards to OTAT and hopefully clearer regulatory pathways and a confirmed partnerhip(s).